Research programme: neurodegenerative disorder therapeutics - Cure Network Dolby Acceleration Partners/Takeda
Latest Information Update: 28 Jul 2025
At a glance
- Originator Gladstone Institutes
- Developer Cure Network Dolby Acceleration Partners; Takeda
- Class Antidementias; Small molecules
- Mechanism of Action Tau protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease; Brain disorders
Most Recent Events
- 28 Jul 2025 No recent reports of development identified for research development in Alzheimer's-disease in Japan
- 28 Jul 2025 No recent reports of development identified for research development in Alzheimer's-disease in USA
- 28 Jul 2025 No recent reports of development identified for research development in Brain-disorders in Japan